Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Forendo Pharma, a Finland-based gynaecological therapy developer based on University of Turku research, on Friday received €5m ($5.6m) from Sunstone Life Sciences Ventures. Forendo’s lead candidate, codenamed FOR-6219, targets endometriosis – a chronic condition affecting women of reproductive age which causes recurring pain and infertility. The drug is being prepared for further clinical testing to…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.